2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Transplantation, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, APL, Translational Research, MDS, Clinical Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult, Animal Model
PAPER

5206 Longitudinal T cell receptor repertoire profiling identifies distinct immune features associated with clinical outcomes in acute myeloid leukemia

Alissa Oakes, PhD, Maria Privratsky, MS2, Rachel M Muti, BSc3, David Frank, MD, PhD4, Andrea Moffitt, PhD5
1 Emory University School of Medicine, Atlanta, Georgia, United States
2 Emory University School of Medicine, Atlanta, Georgia, United States
3 Emory University School of Medicine, Atlanta, Georgia, United States
4 Emory University School of Medicine, Atlanta, Georgia, United States
5 Emory University School of Medicine, Atlanta, Georgia, United States

Background: Acute myeloid leukemia (AML) is an aggressive and highly lethal hematologic malignancy. Although approximately 60% of patients achieve morphologic remission, nearly half relapse within two years. Traditional morphologic assessments fail to detect leukemic cells that persist below the limits of detection, yet modern measurable residual disease (MRD) assays show that low-level disease predicts relapse and survival. Despite its prognostic value, the etiological mechanisms enabling post-therapy leukemic persistence remain poorly understood. Growing evidence suggests that disease progression is not solely driven by leukemic clonal evolution, but also by critical failures in host immune surveillance, particularly T cell dysfunction. We hypothesized that patients achieving durable remission exhibit distinct T cell receptor (TCR) repertoire characteristics compared with patients with relapsed or refractory AML.

Methods: Bulk TCR sequencing was performed on longitudinal bone marrow samples collected from 7 patients with AML at newly diagnosed, and post-induction timepoints. These samples were chosen to represent distinct clinical trajectories: long-term remission (n=4) and refractory or early relapse (n=3). Sequencing data were processed using MiXCR for clonotype assignment, and a custom bioinformatic pipeline developed in R was used to quantify repertoire diversity, richness, clonotype abundance, repertoire overlap, V(D)J gene usage, and longitudinal clonal persistence. 

Results: TCR repertoires differed between patients who achieved long-term remission and those with refractory or relapsed disease. Longitudinal analysis revealed patient-specific remodeling of the TCR repertoire following treatment, with differences in diversity, richness, clonality, and repertoire architecture between outcome groups. Patients with durable remission generally exhibited higher Shannon diversity and repertoire richness, accompanied by lower clonality at both newly diagnosed and post-induction time points, compared with patients who experienced refractory disease or early relapse.

Relative abundance analyses demonstrated dynamic changes in clonotype abundance following treatment, although the magnitude and persistence of these changes varied considerably between patients. Longitudinal tracking identified both persistent and newly emerging clonotypes across all samples, highlighting ongoing remodeling of the adaptive immune repertoire during disease progression and treatment response. Analysis of V and J gene usage revealed patient-specific patterns of gene utilization but did not identify recurrent rearrangements associated with clinical outcome. Together, these findings demonstrate substantial heterogeneity in T-cell repertoire evolution during AML treatment and suggest that differences in repertoire diversity, richness, and clonality may be associated with clinical outcome.

Conclusions: Longitudinal TCR repertoire profiling may identify distinct patterns of T-cell clonal evolution associated with clinical outcome in AML. These findings suggest that adaptive immune responses differ between patients who achieve durable remission and those who experience treatment failure or relapse, with durable remission associated with greater repertoire diversity and lower clonality. The computational framework developed for this study provides a foundation for integrating bulk TCR sequencing with single-cell transcriptomics and ultra-sensitive MRD measurements to determine how T cell dynamics contribute to immune surveillance and AML persistence. Future studies integrating transcriptional state, antigen specificity, and residual disease burden will help define the mechanisms underlying effective anti-leukemic immunity. Improved understanding of these immune responses may identify biomarkers of relapse risk and inform the development of novel immunotherapeutic strategies for AML.

Alissa Oakes, PhD: No relevant conflicts of interest to declare.